Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Revvity, IntelliGenome, Angle, NowDiagnostics, Pramana

NEW YORK — IntelliGenome announced this week that its sputum-free tuberculosis test has obtained breakthrough device designation from the US Food and Drug Administration. The test combines CRISPR with qPCR to detect cell-free DNA of Mycobacterium tuberculosis in blood serum and plasma and can diagnose both pulmonary and extrapulmonary Mtb infections. The firm said it is now well positioned to accelerate a multicenter clinical study underway in the US, Mexico, and Germany. 


Revvity said this week that its board of directors has approved a quarterly dividend of $.07 per share of its common stock, payable on May 9 to all shareholders of record on April 18. 


UK liquid biopsy firm Angle said this week that it expects full-year 2024 revenues to total £2.9 million ($3.6 million), up 31 percent from £2.2 million in 2023. Loss for the year is expected to be £14.0 million, down 30 percent from £20.1 million in 2023. As of Dec. 31, the firm had £10.4 million in cash, enough to take it into 2026. The firm said its current contracts with large pharma companies are progressing well and that it hopes to sign additional contracts with current and new pharma firms this year. 


NowDiagnostics said this week that the company is making its First To Know Syphilis home test available for free through the TakeMeHome initiative. The initiative is a partnership between the National Alliance of State and Territorial AIDS Directors (NASTAD) and the Building Healthy Online Communities (BHOC) that aims to expand access to in-home testing for sexual health. Eligible consumers can order a free First To Know Syphilis test through the initiative and have it delivered to their home. 


Pramana, a company that develops AI-driven health technology, this week said its autonomous whole-slide imaging system will be used in Vanderbilt University Medical Center's pathology lab. Vanderbilt expects the system to advance precision medicine and improve clinical care and patient outcomes. The university also hopes it will enable new insights into disease, resulting in the development of innovative diagnostics and therapies. 


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.